Financial Performance - The company's operating revenue for Q1 2025 was ¥169,909,626.85, a decrease of 9.89% compared to ¥188,550,966.65 in the same period last year[3] - Net profit attributable to shareholders was ¥30,846,730.58, down 7.26% from ¥33,261,190.33 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥23,572,172.58, reflecting an 11.48% decline from ¥26,628,487.47 in the previous year[3] - The basic and diluted earnings per share were both ¥0.09, down 18.18% from ¥0.11 in the same period last year[3] - Operating profit for Q1 2025 was CNY 35,723,206.09, a decline of 6.6% from CNY 38,233,329.04 in Q1 2024[17] - Net profit for Q1 2025 was CNY 35,724,706.09, compared to CNY 38,785,329.04 in Q1 2024, reflecting a decrease of 7.9%[17] - The net profit for Q1 2025 was CNY 30,747,531.52, a decrease of 8.6% compared to CNY 33,180,458.86 in Q1 2024[18] - Basic and diluted earnings per share for Q1 2025 were CNY 0.09, down from CNY 0.11 in Q1 2024, representing a decline of 18.2%[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,559,066,753.89, an increase of 0.52% from ¥2,545,890,506.86 at the end of the previous year[4] - Total current assets increased slightly to CNY 1,963,885,823.60 as of March 31, 2025, compared to CNY 1,938,692,381.54 as of December 31, 2024[11] - Total assets amounted to CNY 2,559,066,753.89 as of March 31, 2025, up from CNY 2,545,890,506.86 as of December 31, 2024[13] - Total liabilities decreased to CNY 234,442,509.03 as of March 31, 2025, from CNY 251,604,573.85 as of December 31, 2024[13] - The total liabilities as of March 31, 2025, included accounts payable of CNY 35,834,620.63, up from CNY 32,185,508.38 at the end of 2024[25] - The total liabilities decreased from CNY 249.82 billion in the previous period to CNY 233.58 billion[26] Cash Flow - The net cash flow from operating activities was negative at -¥19,999,248.29, compared to a positive ¥21,318,126.25 in the same period last year[3] - Cash flow from operating activities for Q1 2025 was negative at CNY -19,999,248.29, compared to a positive CNY 21,318,126.25 in Q1 2024[21] - The cash flow from operating activities showed a net outflow of CNY 18.03 million in Q1 2025, compared to a net inflow of CNY 19.43 million in Q1 2024[30] - Cash and cash equivalents decreased to CNY 110,300,800.63 as of March 31, 2025, from CNY 260,203,598.26 as of December 31, 2024[11] - Total cash and cash equivalents at the end of Q1 2025 were CNY 155,370,347.44, down from CNY 374,626,866.53 at the end of Q1 2024[22] Shareholder Equity - The equity attributable to shareholders increased by 1.34% to ¥2,295,367,065.01 from ¥2,264,929,554.10 at the end of the previous year[4] - Shareholders' equity increased to CNY 2,324,624,244.86 as of March 31, 2025, compared to CNY 2,294,285,933.01 as of December 31, 2024[13] - The total equity increased from CNY 2.28 billion in the previous period to CNY 2.31 billion[26] Research and Development - Research and development expenses for Q1 2025 were CNY 7,251,016.71, slightly down from CNY 7,284,476.64 in Q1 2024[17] - Research and development expenses for Q1 2025 were CNY 5.41 million, slightly down from CNY 5.99 million in Q1 2024[27] Government Subsidies - The company received government subsidies amounting to ¥886,863.49, which are closely related to its normal operations[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,040[8]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,377,665,386.81, representing a 5.80% increase compared to CNY 1,302,151,006.25 in the same period last year[4]. - Net profit attributable to shareholders was CNY 71,173,491.92, up 10.01% from CNY 64,698,264.78 year-on-year[4]. - Net profit for Q1 2025 was ¥308,103,493.23, representing a 5.7% increase from ¥291,385,942.96 in Q1 2024[19]. - Operating profit for Q1 2025 was ¥388,887,519.75, compared to ¥360,336,473.07 in Q1 2024, reflecting a growth of 7.9%[17]. - Total operating costs for Q1 2025 were ¥985,721,577.35, up 4.6% from ¥942,675,572.92 in Q1 2024[17]. - The total comprehensive income for Q1 2025 was ¥308,202,641.86, compared to a loss of ¥111,614,057.04 in Q1 2024[19]. Cash Flow - The net cash flow from operating activities increased by 64.50%, reaching CNY 309,427,488.47 compared to CNY 188,099,292.97 in the previous year[4]. - Cash flow from operating activities for Q1 2025 was ¥309,427,488.47, significantly higher than ¥188,099,292.97 in Q1 2024[21]. - Cash flow from investing activities generated a net inflow of ¥898,307,482.00 in Q1 2025, compared to a net outflow of ¥124,194,022.68 in Q1 2024[22]. - Cash and cash equivalents increased by 52.40% due to the disposal of large-denomination certificates of deposit[6]. - The company’s cash and cash equivalents at the end of Q1 2025 amounted to ¥1,821,944,130.82, up from ¥882,592,747.77 at the end of Q1 2024[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,991,495,157.33, a decrease of 2.31% from CNY 7,156,979,877.32 at the end of the previous year[5]. - The total current assets decreased to ¥2,865,668,136.40 from ¥3,020,575,976.72, a decline of about 5.1%[11]. - The company's inventory decreased significantly from ¥396,311,142.68 to ¥277,478,424.96, a reduction of approximately 30%[11]. - Total liabilities decreased to ¥2,893,345,707.09 from ¥3,367,033,068.94, reflecting a decrease of about 14.0%[13]. - The company's total assets decreased to ¥6,991,495,157.33 from ¥7,156,979,877.32, a decline of approximately 2.3%[13]. - The equity attributable to shareholders increased to ¥1,907,068,733.09 from ¥1,835,796,092.54, an increase of about 3.9%[13]. - The company's long-term investments rose to ¥14,477,303.80 from ¥13,351,135.16, indicating an increase of approximately 8.4%[12]. - The company's short-term borrowings decreased to ¥897,000,000.00 from ¥1,087,220,984.01, a reduction of about 17.5%[13]. Shareholder Information - The company has a total of 11,052 common shareholders at the end of the reporting period[7]. Earnings Per Share - Basic and diluted earnings per share decreased by 22.73% to CNY 0.34 from CNY 0.44 in the same period last year[5]. - The company reported a basic earnings per share of ¥0.34 for Q1 2025, down from ¥0.44 in Q1 2024[19]. Strategic Focus - The company is actively pursuing new product development and technological advancements to enhance its market position[16]. - The company reported a significant increase of 823.31% in net cash flow from investing activities, primarily from the disposal of large-denomination certificates of deposit[6]. - The company's net profit for the first quarter of 2025 is yet to be disclosed, but the focus remains on improving operational efficiency and market expansion strategies[16].

Financial Performance - The company's operating revenue for 2024 reached ¥474,583,693.35, a slight increase of 0.57% compared to ¥471,871,615.15 in 2023[22] - The net profit attributable to shareholders for 2024 was ¥205,271,095.50, reflecting a growth of 0.81% from ¥203,627,027.66 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥205,253,741.46, which is a 3.05% increase from ¥199,187,012.27 in 2023[22] - Cash flow from operating activities amounted to ¥212,208,147.68, up by 5.97% from ¥200,258,125.51 in the prior year[22] - The total assets of the company at the end of 2024 were ¥1,402,448,475.00, a significant increase of 96.79% from ¥712,650,946.12 in 2023[22] - The net assets attributable to shareholders increased to ¥1,234,234,681.98, representing a growth of 112.82% compared to ¥579,954,207.64 at the end of 2023[22] - The basic earnings per share for 2024 were ¥1.53, a decrease of 10.00% from ¥1.70 in 2023[23] - The diluted earnings per share also stood at ¥1.53, reflecting the same 10.00% decline compared to the previous year[23] Dividend Policy - The company plans to distribute a cash dividend of ¥15.00 per 10 shares, totaling approximately ¥240,839,950.50, which accounts for 117.33% of the net profit attributable to shareholders for 2024[5] - The cash dividend amount for the reporting period is 240,839,950.50 RMB, which represents 117.33% of the net profit attributable to ordinary shareholders[151] - The company has a cash dividend policy that prioritizes cash distributions, aiming for at least 50% of the distributable profit to be paid out in cash if there are no major investment plans[147] Market and Product Development - The company is focusing on enhancing brand construction and expanding its multi-channel layout, including strengthening offline sales channels and developing online marketing strategies[32] - The company has established a B2C e-commerce flagship store and partnered with instant retail platforms to diversify its marketing channels[32] - The company aims to enhance consumer education on medication through new media and training for retail chains[32] - The company is focused on developing a product pipeline for home-use external medications, with an emphasis on both generic and innovative products[104] - The company is currently developing several new products, including mupirocin ointment for skin infections and lidocaine cream for local anesthesia[86] Research and Development - The company invested a total of 15.1054 million yuan in R&D during the reporting period, resulting in 2 invention patents and 20 utility model patents granted[33] - Research and development expenses amounted to 15,105.42 million RMB, a decrease of 7.22% from the previous year[54] - The R&D investment amounted to RMB 417.37 million, representing 12.11% of revenue, which is significantly higher compared to peers[90] - Major R&D projects included Polyvinyl Alcohol Eye Drops with an investment of 1.55 million RMB (0.33% of operating revenue), and Oxytetracycline Ear Drops with 0.48 million RMB (0.10% of operating revenue), both showing a 100% increase compared to the previous year[92] Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[8] - The company is committed to optimizing management systems and strengthening risk control to ensure steady business development[31] - The company faces market competition risks, particularly in its external-use drug products, which may impact market share and financial performance if competitors introduce more effective or cost-efficient products[107] - Regulatory changes in the pharmaceutical industry could pose risks, especially if new policies affect pricing or procurement processes, potentially leading to decreased sales and profitability[108] Environmental Compliance - The company has established environmental protection mechanisms and is actively monitoring its emissions[160] - The company has not reported any exceedances of pollutant discharge standards during the monitoring period[162] - The company is committed to maintaining compliance with environmental regulations and improving its sustainability practices[161] - The company faced an administrative penalty in May 2024 for exceeding permitted pollutant discharge concentrations, resulting in a fine of RMB 200,000[172] Governance and Management - The company has established a robust governance structure, holding 8 board meetings, 7 supervisory meetings, and 3 shareholder meetings during the reporting period to ensure effective decision-making[116] - The company has not reported any major discrepancies in governance practices compared to regulatory requirements, indicating compliance and effective management[116] - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 8.565 million yuan[128] - The company has maintained a stable management team with no changes in shareholding[119] Shareholder Commitments - The controlling shareholder, Hong Kong YunJia, has committed to a share lock-up period of 36 months from the date of the company's stock listing, during which no transfer or management of shares will occur[180] - The commitments include a stipulation that any share reduction must be announced 3 trading days in advance[181] - The company will adhere to the latest regulatory rules regarding share lock-up or reduction if there are changes in regulations[182] - The company commits to publicly explaining any failure to fulfill shareholding commitments and will compensate for any losses incurred by investors[186]

Financial Performance - The company's operating revenue for 2024 reached CNY 4,708.99 million, an increase of 14.77% compared to the previous year, primarily driven by increased seed exports and domestic corn seed revenue [4]. - The seed industry revenue amounted to CNY 3,063.33 million, reflecting a growth of 6.52% year-on-year [4]. - Net profit attributable to shareholders was CNY 114.41 million, a decrease of 58.23% from the previous year, mainly due to increased competition and higher research and management expenses [4]. - The company's operating revenue for 2024 reached ¥4,708,992,457.10, representing a 14.77% increase compared to ¥4,102,895,157.95 in 2023 [18]. - Net profit attributable to shareholders decreased by 58.23% to ¥114,405,261.09 in 2024 from ¥273,862,389.94 in 2023 [18]. - Cash flow from operating activities dropped significantly by 76.99% to ¥65,396,069.32 in 2024 from ¥284,164,131.37 in 2023 [18]. - Basic earnings per share decreased by 58.62% to ¥0.12 in 2024 from ¥0.29 in 2023 [18]. - Total assets increased by 14.05% to ¥7,652,407,216.86 at the end of 2024 from ¥6,709,796,938.68 at the end of 2023 [18]. - The company reported a significant decline in quarterly net profit, with Q4 2024 showing a profit of ¥198,738,665.73 after losses in Q2 and Q3 [20]. - The company recorded a net cash outflow from operating activities of ¥633,233,782.96 in Q1 2024, followed by positive cash flows in subsequent quarters [21]. Research and Development - In 2024, the company achieved a research and development investment of 170.83 million yuan, accounting for 5.65% of seed sales revenue [34]. - The company has established multiple key research and development platforms, including a national-level hybrid rice variety creation laboratory and a national enterprise technology center [34]. - The company’s breeding cycle for new varieties typically takes 8-10 years, which can be shortened to 3-4 years using molecular breeding technology [35]. - The company has secured 36 invention patents and 361 plant variety rights, showcasing its strong research and innovation capabilities [46]. - The company has increased its R&D investment, with the proportion of R&D expenses to seed sales revenue rising from 4.9% to 5.65% [133]. - A total of 59 new rice varieties and 16 hybrid corn varieties developed by the company or in collaboration have been approved by national standards, enhancing its competitive edge [133]. Market Strategy and Expansion - The company plans to enhance market competitiveness through increased R&D innovation, brand and service improvement, and internal management optimization [6]. - Future plans include strengthening the integration of the industry chain to improve sales and net profit [6]. - The company is positioned to benefit from supportive government policies aimed at revitalizing the seed industry, which may enhance its competitive edge in the market [28]. - The company aims to create a rapid breeding technology platform for super high-yield hybrid rice, with the goal of producing superior new germplasm [72]. - The company is expanding its overseas business, focusing on markets in Southeast Asia, South Asia, and Africa, while also establishing overseas R&D bases [123]. - The company aims to strengthen its market presence in core businesses like rice, corn, and wheat, targeting to rank among the top three in corn seed sales by the end of the 14th Five-Year Plan [122]. Risk Management - The company faces risks including intensified market competition, new variety development and promotion risks, and changes in industrial policies [6]. - The overall gross margin of the seed business has declined due to increased competition and a higher number of approved varieties in the domestic market [4]. - The company acknowledges the risks associated with new variety development and aims to align its R&D with market demands to ensure successful commercialization [125]. - The company is enhancing its seed production management to mitigate risks from climate change and natural disasters affecting seed quality and yield [126]. - The company has implemented a risk-sharing mechanism with seed producers and farmers to mitigate losses caused by adverse weather conditions [38]. Corporate Governance - The company’s board of directors consists of 8 members, including 4 independent directors, ensuring compliance with governance regulations [140]. - The company maintains independence from its controlling shareholder, with no interference in decision-making or operational activities [139]. - The company has established a sound internal management structure to independently exercise management authority, ensuring separation from the controlling shareholder's operations [151]. - The company has committed to transparency in its financial dealings and governance, as evidenced by the detailed disclosures in its shareholder meetings [154]. - The company reported a total of 45,594 shares held by the chairman, with no changes during the period [156]. Employee Management - The company has implemented a series of employee incentive mechanisms, including stock ownership plans, to enhance employee motivation and align their interests with the company's goals [51]. - The company has a total of 1,829 employees at the end of the reporting period, with 933 in sales, 306 in technical roles, and 304 in production [186]. - The company emphasizes a broad salary structure that aligns compensation with job value and includes comprehensive benefits to attract and retain talent [188]. - The company has implemented training programs focusing on agricultural technology, office skills, legal knowledge, and professional development [189]. Dividend and Profit Distribution - The profit distribution plan proposes a cash dividend of CNY 0.5 per 10 shares (tax included) based on a total share capital of 947,331,751 shares as of December 31, 2024 [6]. - A cash dividend of RMB 0.5 per 10 shares (totaling RMB 47,366,587.55) is proposed for distribution to shareholders based on a total share capital of 947,331,751 shares [195]. - The company plans to retain the remaining undistributed profits for the next fiscal year and will not issue bonus shares [195].

Financial Performance - The company's revenue for Q1 2025 was ¥315,110,184.08, a decrease of 26.58% compared to ¥429,172,675.52 in the same period last year[5] - Net profit attributable to shareholders was ¥15,201,816.26, down 47.29% from ¥28,838,483.33 year-on-year[5] - The basic earnings per share decreased by 46.57% to ¥0.0249 from ¥0.0466 in the same period last year[5] - Total operating revenue decreased to ¥315,110,184.08 from ¥429,172,675.52, representing a decline of approximately 26.6% year-over-year[19] - Net profit for the period was ¥11,227,654.31, down from ¥24,958,440.91, indicating a decline of approximately 55.1% year-over-year[19] - Total comprehensive income attributable to the parent company's owners was CNY 16,503,593.60, a decrease from CNY 28,166,335.28 in the previous period, representing a decline of approximately 41.6%[21] - Basic and diluted earnings per share were both CNY 0.0249, down from CNY 0.0466, indicating a decrease of about 46.5%[21] Cash Flow - The net cash flow from operating activities was -¥17,285,740.15, a decline of 117.05% compared to ¥101,357,363.89 in the previous year[5] - The company reported a decrease in sales expenses to ¥41,035,894.57 from ¥68,543,940.69, reflecting a cost-cutting strategy[19] - Net cash flow from operating activities was negative CNY 17,285,740.15, compared to positive CNY 101,357,363.89 in the previous period, reflecting a significant decline[22] - Cash inflow from investment activities totaled CNY 2,872,578.72, an increase from CNY 1,967,181.53 year-over-year[22] - Cash outflow from investment activities was CNY 25,332,665.92, down from CNY 166,170,288.90, indicating a reduction of approximately 84.8%[22] - Net cash flow from financing activities was negative CNY 59,487,257.84, compared to positive CNY 27,980,960.68 in the previous period, showing a reversal in cash flow[22] - The ending balance of cash and cash equivalents was CNY 44,302,664.88, down from CNY 183,656,176.46, a decrease of about 76.1%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,271,069,770.54, a decrease of 1.30% from ¥4,327,397,080.53 at the end of the previous year[5] - Total liabilities decreased to ¥1,501,478,651.87 from ¥1,570,954,359.63, showing a reduction of about 4.4%[18] - Non-current liabilities totaled ¥332,227,294.64, an increase from ¥254,681,402.98, representing a growth of approximately 30.4%[18] - As of the end of the reporting period, the company's total current assets amounted to approximately CNY 1.75 billion, a decrease from CNY 1.80 billion at the beginning of the period[16] Government Support and Subsidies - The company received government subsidies amounting to ¥27,691,508.52, which positively impacted the financial results[6] Research and Development - Research and development expenses were ¥12,774,780.81, slightly down from ¥13,058,050.61, indicating a continued commitment to innovation despite revenue challenges[19] - Wanbangde Pharmaceutical received approval from the National Medical Products Administration for the supplement application of Cefaclor granules, which is considered to have passed the consistency evaluation of generic drug quality and efficacy, enhancing market competitiveness[11] - The company obtained FDA approval for clinical trials of WP107 (Huperzine A oral solution) for treating generalized myasthenia gravis and WP103 (Huperzine A injection) for treating neonatal hypoxic-ischemic encephalopathy, marking a significant step in new drug development[12] - The FDA granted orphan drug designation for Mecobalamin for the treatment of Amyotrophic Lateral Sclerosis (ALS), providing various incentives for drug development and commercialization in the U.S. market[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,646, with the largest shareholder holding 31.37% of the shares[9] - The company completed the repurchase of 5 million shares in March 2022, which were subsequently canceled due to the inability to complete the employee stock ownership plan within the effective period[15]

Financial Performance - The company's operating revenue for Q1 2025 was ¥185,003,691.08, a decrease of 59.88% compared to ¥461,142,866.49 in the same period last year[4]. - Total operating revenue for the current period is $185.00 million, a decrease of 60.0% compared to $461.14 million in the previous period[34]. - Net profit for the current period is a loss of $84.81 million, compared to a loss of $87.01 million in the previous period, showing a slight improvement[35]. - Total comprehensive income for the current period is a loss of $84.81 million, compared to a loss of $87.01 million in the previous period[35]. - The net loss attributable to shareholders was ¥79,033,132.09, an improvement of 10.17% from a loss of ¥87,978,120.27 in the previous year[4]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 80.84%, reaching -¥43,454,651.37 compared to -¥226,842,479.55 in the same period last year[4]. - Operating cash flow for the current period is a net outflow of $43.45 million, compared to a net outflow of $226.84 million in the previous period, indicating improved cash flow management[36]. - Cash and cash equivalents at the end of the period are $123.19 million, down from $201.99 million at the end of the previous period[37]. - The company's cash and cash equivalents decreased to CNY 197,399,724.32 from CNY 236,892,033.01, reflecting a reduction of about 16.7%[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,989,978,321.60, a decrease of 1.98% from ¥6,111,256,769.69 at the end of the previous year[4]. - Current assets totaled CNY 4,475,672,938.32, down from CNY 4,582,547,569.58, indicating a decline of approximately 2.3%[30]. - Total liabilities were CNY 5,012,332,501.48, a slight decrease from CNY 5,079,353,723.68, indicating a reduction of about 1.3%[31]. - The company's equity attributable to shareholders decreased to CNY 1,046,350,361.16 from CNY 1,094,830,790.13, a decline of approximately 4.4%[32]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,841[25]. - The company's basic and diluted earnings per share were both -¥0.11, an improvement of 8.33% from -¥0.12 in the same period last year[4]. - Basic and diluted earnings per share for the current period are both -$0.11, compared to -$0.12 in the previous period[36]. Research and Development - Research and development expenses decreased by 90.42%, reflecting reduced investment in R&D projects[13]. - Research and development expenses decreased to $1.10 million from $11.48 million, reflecting a 90.4% reduction[34]. Other Income and Expenses - The company reported a 244.47% increase in non-operating income, primarily due to an increase in litigation compensation received[20]. - Financial expenses increased by 41.53%, primarily due to an increase in loan penalty provisions[14]. - The company reported a credit impairment loss of $4.80 million, a significant change from a gain of $4.63 million in the previous period[35]. Inventory and Contract Liabilities - The company experienced a 44.67% increase in contract liabilities, mainly due to pre-received project payments[9]. - The company’s contract liabilities increased to CNY 94,949,398.02 from CNY 65,633,948.58, reflecting an increase of approximately 44.5%[31]. - The company’s inventory increased to CNY 570,505,244.09 from CNY 524,028,316.24, showing a growth of about 8.8%[30]. Regulatory and Restructuring Actions - The company reported a fine of CNY 8.5 million due to false disclosures in annual reports from 2017 to 2021[28]. - The company signed a restructuring agreement with Shanghai Hengcen Enterprise Management Consulting Co., Ltd. and Shanghai Kangheng Environmental Co., Ltd. as the selected investors for its restructuring process[28].

Financial Performance - The company's revenue for Q1 2025 was ¥835,321,277.94, representing a 24.13% increase compared to ¥672,962,046.88 in the same period last year[4] - The net profit attributable to shareholders decreased by 87.62% to ¥2,196,667.64 from ¥17,744,469.19 year-on-year[4] - The company achieved operating revenue of CNY 835.32 million, an increase of 24.13% compared to the same period last year[17] - The net profit attributable to shareholders decreased by 87.62% to CNY 2.19 million, impacted by increased competition and rising management expenses[17] - The net profit for the current period was a loss of ¥16,847,296.05, compared to a profit of ¥16,766,262.77 in the previous period, indicating a shift in profitability[22] - The total comprehensive income attributable to the parent company was CNY 1,902,512.68, down from CNY 14,411,663.28 year-over-year[23] Cash Flow - The net cash flow from operating activities was -¥776,835,154.94, a decline of 22.68% compared to -¥633,233,782.96 in the previous year[4] - The cash inflow from operating activities increased by 17.92% to ¥798,756,372.58, driven by higher cash receipts from sales[11] - The cash outflow from operating activities rose by 20.22% to ¥1,575,591,527.52, primarily due to increased payments for seeds[11] - Operating cash flow generated a net outflow of CNY -776,835,154.94, compared to CNY -633,233,782.96 in the previous period[25] - Cash inflow from operating activities totaled CNY 798,756,372.58, an increase from CNY 677,385,806.11 year-over-year[24] - Cash outflow from operating activities was CNY 1,575,591,527.52, up from CNY 1,310,619,589.07 in the previous period[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,037,242,335.60, down 8.04% from ¥7,652,407,216.86 at the end of the previous year[4] - Current assets decreased to ¥5,300,793,007.73 from ¥5,913,823,531.24, a decline of approximately 10.3%[20] - Total liabilities decreased to ¥4,429,353,093.63 from ¥5,030,356,423.14, representing a reduction of about 11.9%[21] - Cash and cash equivalents dropped to ¥972,369,719.79 from ¥1,600,073,995.25, a decrease of approximately 39.1%[20] - Accounts receivable increased to ¥737,068,001.49 from ¥552,806,527.11, reflecting a growth of about 33.4%[20] - Inventory decreased to ¥2,790,168,125.20 from ¥2,988,861,416.06, a decline of approximately 6.6%[20] - Long-term borrowings rose to ¥300,231,000.00 from ¥138,974,000.00, an increase of about 116.5%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 49,422[13] - The largest shareholder, China Seed Group Co., Ltd., holds 20.51% of the shares, totaling 194,294,026 shares[13] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Jia Guilan, owning 6.92%[13] - The company has a total of 10 major unrestricted shareholders, with significant holdings in common shares[14] - The number of restricted shares at the end of the period was 51,434,182, with some shares set to be released from lock-up in the future[16] Operational Challenges - The company reported a significant increase in operating costs, which rose by 33.82% to ¥722,729,826.32 due to increased orders and export business[9] - The company is facing challenges in its seed business due to increased homogenization and competition, leading to a decline in overall gross margin[17] - The company has seen an increase in seed exports and grain order business, contributing to revenue growth despite profit decline[17] Board and Governance - The company plans to delay the re-election of the board of directors and supervisory board to ensure continuity and stability[18]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 323,825,679.43, representing a year-on-year increase of 13.28% compared to CNY 285,856,920.93 in the same period last year[4]. - Net profit attributable to shareholders decreased by 34.48% to CNY 12,410,454.38 from CNY 18,942,786.54 in the previous year[4]. - The basic and diluted earnings per share fell by 36.84% to CNY 0.12 from CNY 0.19 year-on-year[4]. - Net profit for Q1 2025 was ¥13,408,194.59, a decrease of 29.1% from ¥18,942,786.54 in Q1 2024[18]. - Basic earnings per share for Q1 2025 were ¥0.12, down from ¥0.19 in Q1 2024[19]. Cash Flow - The net cash flow from operating activities decreased by 24.11% to CNY 36,431,760.31, down from CNY 48,005,388.05 in the same period last year[4]. - Cash inflow from operating activities totaled ¥369,597,366.82 in Q1 2025, compared to ¥318,152,401.34 in Q1 2024, marking an increase of 16.1%[21]. - The net cash flow from operating activities was $36,431,760.31, a decrease of 24% compared to $48,005,388.05 in the previous period[22]. - Cash outflow from investing activities totaled $8,930,252.51, significantly lower than $123,597,066.40 in the prior period, indicating a reduction in capital expenditures[22]. - The ending balance of cash and cash equivalents increased to $100,153,573.23, compared to $53,476,670.17 at the end of the previous period, reflecting a growth of 87%[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,168,704,110.46, a 1.19% increase from CNY 2,143,200,598.80 at the end of the previous year[5]. - The company's current assets reached CNY 631.45 million, up from CNY 598.96 million, indicating an increase of approximately 5.4%[13]. - Total liabilities as of the end of the reporting period were ¥1,091,858,442.14, slightly up from ¥1,079,291,600.20 in the previous period[15]. - The company's total liabilities increased to CNY 631.45 million, up from CNY 598.96 million, indicating a growth of about 5.4%[12]. Investment and Equity - The decrease in net profit was primarily due to increased investment losses related to long-term equity investments in WeiMeiZi[7]. - The equity attributable to shareholders increased by 1.20% to CNY 1,006,886,428.59 from CNY 994,947,499.08 at the end of the previous year[5]. - Total equity attributable to shareholders reached ¥1,006,886,428.59, an increase from ¥994,947,499.08 year-over-year[15]. - The company reported a decrease in investment income, with a loss of ¥6,383,206.17 in Q1 2025 compared to a loss of ¥2,670,034.45 in Q1 2024[18]. Research and Development - Research and development expenses increased to ¥12,064,343.21 in Q1 2025, compared to ¥7,654,021.47 in Q1 2024, reflecting a growth of 57.5%[17]. Other Financial Metrics - The weighted average return on equity decreased by 0.28 percentage points to 1.24% from 1.52%[5]. - Non-recurring gains and losses amounted to CNY 947,295.37, with significant contributions from government subsidies and other non-operating income[6]. - Deferred income tax liabilities increased to ¥47,598,651.97 in Q1 2025 from ¥32,826,626.46 in Q1 2024, indicating a rise of 44.9%[15]. - The company reported a significant increase in deferred tax assets, rising to CNY 22.01 million from CNY 7.51 million, reflecting a growth of approximately 194.7%[13].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 607.69 million, a decrease of 18.68% compared to CNY 747.27 million in the same period last year[4] - The net profit attributable to shareholders was CNY 32.76 million, down 5.43% from CNY 34.64 million year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 23.84 million, a decline of 25.17% from CNY 31.85 million in the previous year[4] - The basic and diluted earnings per share were both CNY 0.0872, down 5.43% from CNY 0.0922 year-on-year[4] - Operating profit for Q1 2025 was CNY 53,204,225.88, a decline of 15.4% from CNY 62,846,007.65 in Q1 2024[18] - Net profit for Q1 2025 after tax was CNY 41,722,758.55, compared to CNY 48,343,509.47 in Q1 2024, reflecting a decrease of 13.7%[18] - The net profit for the first quarter of 2025 is approximately ¥41.72 million, a decrease of 13.4% compared to ¥48.34 million in the same period of 2024[19] - The net profit attributable to the parent company's shareholders is ¥32.76 million, down from ¥34.64 million, reflecting a decline of 5.1% year-over-year[19] - The total comprehensive income for the first quarter is ¥40.70 million, compared to ¥45.30 million in the previous year, indicating a decrease of 10.5%[19] - The basic and diluted earnings per share for the first quarter are both ¥0.0872, down from ¥0.0922 in the first quarter of 2024, representing a decline of 5.4%[19] Cash Flow and Investments - The net cash flow from operating activities was negative CNY 14.11 million, a significant decrease of 111.89% compared to CNY 118.75 million in the same period last year[4] - Cash flow from operating activities shows a net outflow of approximately ¥14.11 million, a significant drop from a net inflow of ¥118.75 million in the same quarter last year[23] - Cash inflow from investment activities is approximately ¥1.40 billion, compared to ¥653.69 million in the previous year, marking a substantial increase[24] - The net cash flow from investment activities is ¥139.66 million, a turnaround from a net outflow of ¥118.29 million in the first quarter of 2024[24] - The cash and cash equivalents at the end of the period stand at approximately ¥334.66 million, down from ¥412.92 million at the end of the first quarter of 2024[24] - The decline in cash flow from operating activities was primarily due to the disposal of a controlling subsidiary and a decrease in cash received from sales and services[6] - The company reported a decrease in cash inflow from sales of goods and services, totaling ¥688.23 million, down 17.5% from ¥834.16 million in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3.69 billion, an increase of 1.20% from CNY 3.65 billion at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to CNY 3,690,749,265.36, a slight increase from CNY 3,646,890,333.32 at the end of 2024[15] - Total liabilities were CNY 248,456,806.31 as of March 31, 2025, compared to CNY 246,173,909.18 at the end of 2024, indicating a marginal increase of 0.9%[15] - The company's equity attributable to shareholders increased to CNY 3,294,545,697.34 as of March 31, 2025, from CNY 3,261,815,914.99 at the end of 2024, reflecting a growth of 1.0%[15] Shareholder Information - Shareholder Wei Zhonghao holds 30.53% of the shares, amounting to 117,014,266 shares[9] - The company repurchased 7,600,000 shares, accounting for 1.9831% of the total share capital[10] Research and Development - Research and development expenses for Q1 2025 were CNY 8,614,052.18, down 13.9% from CNY 10,016,534.27 in Q1 2024[18] Fair Value and Market Activity - The company reported a fair value gain of CNY 8,212,885.93 in Q1 2025, compared to a loss of CNY 899,765.15 in Q1 2024, indicating a significant turnaround[18] - The company has not reported any new product launches or significant market expansion strategies during this quarter[25]

石家庄科林电气股份有限公司2025 年第一季度报告 证券代码：603050 证券简称：科林电气 石家庄科林电气股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同 | | --- | --- | --- | --- | | | | | 期增减变动幅度 | | | | | (%) | | 营业收入 | 911,806,138.20 | 752,199,793.92 | 21.22% | | 归属于上市公司股东的净利 润 | 72,705,684.06 | 67 ...